OBJECTIVE: The aim of this study was to evaluate patient compliance with phlebotomy therapy of hemochromatosis-associated iron overload. METHODS: We reviewed medical records of white adults with hemochromatosis and iron overload diagnosed during medical care. We defined three elements of compliance: 1) achieving iron depletion (serum ferritin </= 20 ng/ml); 2) timeliness of phlebotomies on a weekly or biweekly schedule to achieve iron depletion; and 3) participation in therapy to maintain serum ferritin </= 50 ng/ml. We evaluated associations of timeliness of phlebotomy and participation in maintenance therapy with these variables: age at diagnosis, sex, pretreatment serum ferritin concentration, HFE genotype, units of blood removed to achieve iron depletion, and presence or absence of cirrhosis at diagnosis. RESULTS: A total of 118 patients were evaluable for iron depletion and 142 for maintenance therapy; 96.6% achieved iron depletion, and 33.1% and 43.2% followed weekly and biweekly schedules, respectively. Timeliness was not significantly associated with the variables we evaluated. In the first year of maintenance therapy, 84.0% of patients complied; the percentage of C282Y homozygotes complying was significantly greater than that of other patients. Average compliance with maintenance therapy decreased 6.8% annually; the mean follow-up after achieving iron depletion was 4.1 +/- 2.8 yr (range 0.6-9.7 yr). CONCLUSIONS: Most patients with hemochromatosis diagnosed in medical care achieve iron depletion with phlebotomy; one-third tolerate and adhere to weekly phlebotomy. There is a constant rate of decline in the percentage of patients who comply with maintenance therapy.
OBJECTIVE: The aim of this study was to evaluate patient compliance with phlebotomy therapy of hemochromatosis-associated iron overload. METHODS: We reviewed medical records of white adults with hemochromatosis and iron overload diagnosed during medical care. We defined three elements of compliance: 1) achieving iron depletion (serum ferritin </= 20 ng/ml); 2) timeliness of phlebotomies on a weekly or biweekly schedule to achieve iron depletion; and 3) participation in therapy to maintain serum ferritin </= 50 ng/ml. We evaluated associations of timeliness of phlebotomy and participation in maintenance therapy with these variables: age at diagnosis, sex, pretreatment serum ferritin concentration, HFE genotype, units of blood removed to achieve iron depletion, and presence or absence of cirrhosis at diagnosis. RESULTS: A total of 118 patients were evaluable for iron depletion and 142 for maintenance therapy; 96.6% achieved iron depletion, and 33.1% and 43.2% followed weekly and biweekly schedules, respectively. Timeliness was not significantly associated with the variables we evaluated. In the first year of maintenance therapy, 84.0% of patients complied; the percentage of C282Y homozygotes complying was significantly greater than that of other patients. Average compliance with maintenance therapy decreased 6.8% annually; the mean follow-up after achieving iron depletion was 4.1 +/- 2.8 yr (range 0.6-9.7 yr). CONCLUSIONS: Most patients with hemochromatosis diagnosed in medical care achieve iron depletion with phlebotomy; one-third tolerate and adhere to weekly phlebotomy. There is a constant rate of decline in the percentage of patients who comply with maintenance therapy.
Authors: Ronald T Acton; James C Barton; Leah V Passmore; Paul C Adams; Gordon D McLaren; Catherine Leiendecker-Foster; Mark R Speechley; Emily L Harris; Oswaldo Castro; Jacob A Reiss; Beverly M Snively; Barbara W Harrison; Christine E McLaren Journal: Clin Gastroenterol Hepatol Date: 2008-06-27 Impact factor: 11.382
Authors: Mark Speechley; James C Barton; Leah Passmore; Helen Harrison; David M Reboussin; Emily L Harris; Charles A Rivers; Margaret Fadojutimi-Akinsiku; Lari Wenzel; Sharmin Diaz Journal: Genet Test Mol Biomarkers Date: 2009-12
Authors: Victor R Gordeuk; David M Reboussin; Christine E McLaren; James C Barton; Ronald T Acton; Gordon D McLaren; Emily L Harris; Jacob A Reiss; Paul C Adams; Mark Speechley; Pradyumna D Phatak; Phyliss Sholinsky; John H Eckfeldt; Wen-Pin Chen; Leah Passmore; Fitzroy W Dawkins Journal: Am J Hematol Date: 2008-08 Impact factor: 10.047
Authors: Pradyumna Phatak; Pierre Brissot; Mark Wurster; Paul C Adams; Herbert L Bonkovsky; John Gross; Peter Malfertheiner; Gordon D McLaren; Claus Niederau; Alberto Piperno; Lawrie W Powell; Mark W Russo; Ulrich Stoelzel; Wolfgang Stremmel; Louis Griffel; Nicola Lynch; Yiyun Zhang; Antonello Pietrangelo Journal: Hepatology Date: 2010-11 Impact factor: 17.425